Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
308.8 USD | +0.45% | +3.07% | +7.42% |
May. 28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
May. 28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.42% | 165B | |
+42.30% | 748B | |
+33.95% | 598B | |
-5.83% | 356B | |
+18.28% | 325B | |
+4.86% | 283B | |
+17.42% | 245B | |
+9.10% | 211B | |
-4.25% | 209B | |
+2.76% | 166B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia